Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 10, 2026
Delta Air Lines (DAL) Earnings Preview for the Second Quarter of 2026

Delta Air Lines (DAL) Earnings Preview for the Second Quarter of 2026

Key Takeaways

  • Delta Air Lines is set to report second-quarter 2026 results on July 10, 2026, before market open.
  • Consensus estimates point to adjusted earnings per share of approximately $1.48 to $1.49.
  • Revenue is projected to rise about 10% year-over-year, supported by strong travel demand.
  • Investors will focus on unit revenue trends, fuel costs, and any updates to full-year guidance.
  • Delta has consistently delivered results in line with or above expectations in recent quarters.
  • The stock has historically shown volatility around earnings announcements.

Earnings Context and Why It Matters

Delta Air Lines operates in a highly competitive airline industry where quarterly results reflect broader economic conditions, fuel prices, and consumer travel patterns. The second quarter typically benefits from summer travel peaks, making it a key period for assessing demand strength and pricing power. Following solid March quarter performance, investors are watching for continued momentum in passenger revenue and operational efficiency. Strong results could reinforce confidence in the company’s recovery trajectory and long-term targets.

Earnings Expectations

Analysts expect DAL to report adjusted earnings per share between $1.47 and $1.49 for the June quarter. Revenue is anticipated to increase roughly 10% compared with the same period last year, driven by robust leisure and business travel demand. The company has not issued formal guidance for the quarter but has historically provided updates on capacity, unit revenues, and cost management during earnings calls. Investors will also monitor comparisons to prior-year results and any commentary on fuel hedging or labor expenses. Delta reported March quarter earnings in line with guidance on April 8, 2026, with revenue beating expectations amid broad demand strength. I also checked this using Tickeron’s AI tools to see how the stock compares to others in the industry.

Market Reaction and Investor Sentiment

Sentiment heading into the report appears cautiously optimistic, with analysts highlighting resilient travel demand and Delta’s strong competitive position. The stock often experiences heightened volatility around earnings, with moves driven by how results compare to consensus and any forward-looking commentary. Recent quarters have seen positive reactions when revenue or margins exceeded expectations. Key risk factors include potential softening in premium cabin demand or unexpected cost pressures.

Using AI Tools to Refine the View

In preparing for this report, I turned to Tickeron’s AI Screener to filter peers and identify relevant technical and fundamental patterns across the airline sector. This helped confirm where DAL stands relative to broader industry trends without relying solely on manual screening. AI Screener

Forward Outlook and Key Factors to Monitor

Following the earnings release, attention will shift to Delta’s updated outlook for the remainder of 2026. Investors should watch for any revisions to capacity plans, fuel cost assumptions, and long-term earnings targets. Demand signals from booking trends and yield performance will provide insight into the sustainability of recent growth. Margin pressures from labor agreements and maintenance costs remain important considerations. Broader industry dynamics, including competitor capacity and economic indicators affecting travel, could influence sentiment. The company’s ability to execute on premium product initiatives and operational reliability will also factor into assessments of future performance. One thing that stands out is how consistently the airline has navigated cost pressures in prior periods.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DAL

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for DAL turns positive, indicating new upward trend

DAL saw its Momentum Indicator move above the 0 level on July 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 75 similar instances where the indicator turned positive. In of the 75 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for DAL just turned positive on August 03, 2026. Looking at past instances where DAL's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

DAL moved above its 50-day moving average on July 24, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DAL advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for DAL moved out of overbought territory on July 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DAL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

DAL broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for DAL entered a downward trend on August 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. DAL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.773) is normal, around the industry mean (4.445). P/E Ratio (15.254) is within average values for comparable stocks, (19.324). DAL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (3.402). Dividend Yield (0.009) settles around the average of (0.019) among similar stocks. P/S Ratio (0.884) is also within normal values, averaging (0.632).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Delta Air Lines (NYSE:DAL), United Airlines Holdings (NASDAQ:UAL), Southwest Airlines Co (NYSE:LUV), American Airlines Group (NASDAQ:AAL), JetBlue Airways Corp (NASDAQ:JBLU).

Industry description

Airlines industry comprises passenger air transportation, including scheduled and non-scheduled routes. This can include charter airlines, as well as regular commuter ones. Discount pricing and the rise of low-cost carriers over recent decades have expanded the industry by making its services accessible to a much larger global population, compared to the older days when airline travel was a relative luxury for many people in the world. Delta Air Lines Inc., Southwest Airlines Co and United Continental Holdings, Inc. are some of the airlines with the largest stock market capitalizations in the U.S.

Market Cap

The average market capitalization across the Airlines Industry is 11.73B. The market cap for tickers in the group ranges from 9.36K to 1.51T. AZULD holds the highest valuation in this group at 1.51T. The lowest valued company is KLMR at 9.36K.

High and low price notable news

The average weekly price growth across all stocks in the Airlines Industry was 3%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -15%. ULCC experienced the highest price growth at 9%, while RJET experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the Airlines Industry was -15%. For the same stocks of the Industry, the average monthly volume growth was -50% and the average quarterly volume growth was -42%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 58
Price Growth Rating: 45
SMR Rating: 66
Profit Risk Rating: 71
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
DAL
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of scheduled air transportation for passengers, freight, and mail services

Industry Airlines

Profile
Details
Industry
Airlines
Address
Post Office Box 20706
Phone
+1 404 715-2600
Employees
103000
Web
https://www.delta.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Delta Air Lines (DAL) Earnings Preview for the Second Quarter of 2026